The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Akpinar, Seval; Dogu, Mehmet; ÇELİK, SERHAT; Ekinci, Omer; Hindilerden, Ipek; Dal, Mehmet; Davulcu, Eren; Tekinalp, Atakan; Hindilerden, Fehmi; Ozcan, Busra; HACIBEKİROĞLU, TUBA; ERKURT, MEHMET; Bagci, Metin; Namdaroglu, Sinem; Korkmaz, Gulten; Bilgir, Oktay; ÇAĞLIYAN, GÜLSÜM; Ozturk, Hacer; Serin, Istemi; Tiryaki, Tarik; ÖZATLI, DÜZGÜN; Korkmaz, Serdal; Ulas, Turgay; Eser, Bulent; TURGUT, BURHAN; Altuntas, Fevzi

doi:10.1016/j.clml.2021.09.010

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Akpinar S., Dogu M. H., ÇELİK S., Ekinci O., Hindilerden I. Y., Dal M. S., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.22, no.3, pp.169-173, 2022 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 22 Issue: 3
Publication Date: 2022
Doi Number: 10.1016/j.clml.2021.09.010
Journal Name: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Page Numbers: pp.169-173
Keywords: Chronic lymphocytic leukemia, Bruton tyrosine kinase, Ibrutinib, Relapsed/refractory, p53 mutation
Erciyes University Affiliated: No

Abstract

We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.